Syndax Pharmaceuticals IPO

3/2/2016

IPO

$52,800,000

The principal purposes of this offering are to obtain additional capital to support our operations, establish a public market for our common stock and to facilitate our future access to the public capital markets. We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, for the following purposes: approximately $28.0 million to support the clinical trials of entinostat in combination with Keytruda® (pembrolizumab), atezolizumab and avelumab through the expected completion date of the two Phase 2 clinical trials; approximately $10.0 million to support additional clinical trials of entinostat in combination with immune checkpoint inhibitors; approximately $19.0 million to support the Phase 3 clinical trial of entinostat in advanced HR+ breast cancer through the primary endpoint of overall survival data; approximately $16.0 million to conduct activities to support the filing of a New Drug Application for

Publicly-held

Biopharmaceutical

400 Totten Pond Road 110
Waltham, MA 02451
USA

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.